idiopathic pulmonary fibrosis
Conditions
Interventions
None listed
Sponsors
Kurume University, School of Medicine
Department of Radiology and Center for Diagnostic Imaging, Kurume University, School of Medicine Department of Radiology, Kinki Central Hospital of the Mutual Aid Association of Public School Teachers Second Department of Internal Medicine, Nagasaki University, School of Medicine Department of Pathology, Nagasaki University, School of Medicine Department of Respiratory Medicine and Allergy, Tosei General Hospital Department of Respiratory Medicine, Graduate School of Medicine, Osaka City Un
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The case with idiopathic pulmonary fibrosis who visited to the hospitals participated to this study. Patients who fulfilled all of the following criteria 1. Age is more than 40 years old. 2. After receiving enough explanations about participation in the study, there was the document consent by free will of patients thorough his enough understanding. 3. Patient who was diagnosed as idiopathic pulmonary fibrosis by criteria of this study 4. Disease activity is stable at registration 5. Patient who need treatment with nintedanib 6. Patient who can be treated with nintedanib within 2 weeks from obtaining informed consent
Exclusion criteria
Exclusion criteria: The patients who fulfilled one of the following criteria 1. Pregnant women. 2. Patient who was determined as ineligible by the investigator or the subinvestigator. 3. Patients treated with the following drug at the start of observation. Corticosteroid (more than 10 mg per day in term of prednizolone) Immunosuppressant N-acetylcysteine Pirfenidone Study drug for idiopathic pulmonary fibrosis 4. Case with exclusion disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The correlation between serum periostin level and change of pulmonary function | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The correlation between serum periostin level and clinical data except for pulmonary function 2. Predictors of overall survival and progression-free-survival | — |
Countries
Japan
Contacts
Public ContactMasaki Okamoto
Kurume University, School of Medicine Division of Respirology, Neurology and Rheumotology, Department of Internal Medicine
Outcome results
None listed